FibroGen Inc expected to post a loss of 68 cents a share - Earnings Preview

Kyntra Bio

04/11/2023 01:30

* FibroGen Inc  FGEN.OQ   FGEN.O  is expected to show a rise
in
quarterly revenue when it reports  results 
    * The San Francisco California-based  company is expected to
report  a 134.1% increase in revenue to $36.84 million from
$15.74 million a year ago, according to the mean estimate from 4
analysts, based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for FibroGen Inc is for
a
loss of 68 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 3
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for FibroGen
Inc is
$2​, above​ its last closing price of $0.65. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.70       -0.70      -0.90     Missed  -28
 Mar. 31 2023  -0.72       -0.75      -0.81     Missed  -7.5
 Dec. 31 2022  -0.93       -0.94      -0.70     Beat    25.4​
 Sep. 30 2022  -0.79       -0.81      -0.98     Missed  -21
 ​​Jun.        -0.93       -0.94      -0.78     Beat    16.7
 30 2022                                                
 Mar. 31 2022  -0.82       -0.83      -0.68     Beat    18.2​
 Dec. 31 2021  -0.63       -0.66      -1.45     Missed  -118.7
 Sep. 30 2021  0.06        -0.01      0.54      Beat    9,100
 This summary was machine generated November 4 at 01:30 GMT.  All
figures in US dollars  unless otherwise stated